On July 20, JD Health rose 3.22% in regular trading, trading at HK$38.36/share, with turnover of approximately HK$39.28 million. The rally was driven by the company's AI doctor \"Dawei\" and evidence-based medicine AI product \"JD Zhiyi\" debuting at the World Artificial Intelligence Conference (WAIC) on July 17, becoming a focal point in the health AI space.

Beyond the WAIC showcase, JD Health has recently secured a series of strategic partnerships. The company signed an agreement with Everest Medicines on innovative drug launches and patient lifecycle management, and partnered with Sinocare to build an AI medical device product matrix exceeding RMB 1 billion over three years. Additionally, its collaboration with Yuwell Medical was upgraded, targeting RMB 10 billion in sales over three years while integrating AI medical devices into its HomeCare service system. UBS maintains a \"Buy\" rating on JD Health, citing established competitive advantages in user base and supply chain.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)